(UroToday.com) The field of advanced prostate cancer has rapidly progressed over the past 15 years. In the past 5 years, there has been considerable development in the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC), including chemotherapy and novel hormonal therapies (NHT). Each of these has proven survival benefits compared to the historic standard of androgen deprivation therapy (ADT) alone. However, the uptake of these guideline-recommended treatment approaches with level 1 data is unknown. In a plenary abstract presentation in the Poster Highlights Session: Prostate Cancer session at the 2021 ASCO GU Cancers Symposium, Dr. Stephen Freedland and colleagues assessed utilization and outcomes for patients with mCSPC in the Veterans Health Administration system.